Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Alzheimer's disease is characterized by amyloid-beta (Aβ) plaques and neurofibrillary tangles. The humanized monoclonal antibody solanezumab was designed to increase the clearance from the brain of soluble Aβ, peptides that may lead to toxic effects in the synapses and precede the deposition of fibrillary amyloid. METHODS: We conducted a double-blind, placebo-controlled, phase 3 trial involving patients with mild dementia due to Alzheimer's disease, defined as a Mini-Mental State Examination (MMSE) score of 20 to 26 (on a scale from 0 to 30, with higher scores indicating better cognition) and with amyloid deposition shown by means of florbetapir positron-emission tomography or Aβ1-42 measurements in cerebrospinal fluid. Patients were randomly assigned to receive solanezumab at a dose of 400 mg or placebo intravenously every 4 weeks for 76 weeks. The primary outcome was the change from baseline to week 80 in the score on the 14-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog14; scores range from 0 to 90, with higher scores indicating greater cognitive impairment). RESULTS: A total of 2129 patients were enrolled, of whom 1057 were assigned to receive solanezumab and 1072 to receive placebo. The mean change from baseline in the ADAS-cog14 score was 6.65 in the solanezumab group and 7.44 in the placebo group, with no significant between-group difference at week 80 (difference, -0.80; 95% confidence interval, -1.73 to 0.14; P=0.10). As a result of the failure to reach significance with regard to the primary outcome in the prespecified hierarchical analysis, the secondary outcomes were considered to be descriptive and are reported without significance testing. The change from baseline in the MMSE score was -3.17 in the solanezumab group and -3.66 in the placebo group. Adverse cerebral edema or effusion lesions that were observed on magnetic resonance imaging after randomization occurred in 1 patient in the solanezumab group and in 2 in the placebo group. CONCLUSIONS: Solanezumab at a dose of 400 mg administered every 4 weeks in patients with mild Alzheimer's disease did not significantly affect cognitive decline. (Funded by Eli Lilly; EXPEDITION3 ClinicalTrials.gov number, NCT01900665 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the expedition3 trial (NCT01900665), aimed at further validating the drug’s efficacy in patients with mild AD, the drug was declared unsuccessful in 2016, as it failed to meet its primary endpoints.457–459”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [459]
In the citing paper
“In three completed phase 3 clinical trials (EXPEDITION, EXPEDITION2, EXPEDITION3), solanezumab did not significantly reduce the decline in cognition or function (e.g., activities of daily living and community involvement) in patients who had received a clinical diagnosis of mild-to-moderate AD [79].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [79]
In the citing paper
“Florbetapir PET analysis did not show a reduction in brain amyloid deposits with solanezumab [45, 46].”
From Clinical trials of new drugs for Alzheimer disease (2020) · cites this paper as [46]
In the citing paper
“anti-Aβ mAbs that predominantly bind to monomeric Aβ do not mediate substantial removal of plaque and lack clinical efficacy”
From The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics (2022) · cites this paper as [42]
In the citing paper
“A third phase 3 trial in mild AD also failed to demonstrate a significant benefit on the primary endpoint (Honig et al., 2018).”
From Alzheimer Disease: An Update on Pathobiology and Treatment Strategies (2019) · cites this paper as Honig et al., 2018
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
Hyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.10.007 · Cited by 3,092
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Measurement of Functional Activities in Older Adults in the Community
Pfeffer, R. I., Kurosaki, T. T., Harrah, C. H., Chance, J. M., & Filos, S. (1982) · Journal of Gerontology · doi:10.1093/geronj/37.3.323 · Cited by 2,972
The molecular pathology of Alzheimer's disease
Selkoe, D. J. (1991) · Neuron · doi:10.1016/0896-6273(91)90052-2 · Cited by 2,708
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Self-citation
Cited by
Items 801–900 of 999
Desai, U. S., Gomes, D. A., Chandler, J., Ye, W., Daly, M., Kirson, N. Y., & Dennehy, E. B. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2394602 · Cited by 4
Niazi, S. K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251810211 · Cited by 3
“Similarly, the EXPEDITION trials involving solanezumab, another anti-amyloid therapy, demonstrated modest reductions in amyloid plaques but failed to show any significant clinical benefits, questioning the utility of amyloid-beta as a reliable biomarker for therapeutic success [11].”
BackgroundArmstrong, C., Luo, D., Gretzinger, A., Pandey, D., Lipchik, A. M., Todi, S. V., & Dutta, A. K. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00220 · Cited by 3
LATE, Hippocampal Sclerosis, and Primary Age-related Tauopathy
Ramanan, V. K., & Graff‐Radford, J. (2024) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000001499 · Cited by 6
Moseholm, K. F., Meineche, J. T., & Jensen, M. K. (2024) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000968 · Cited by 3
Mishra, A. K., Srivastava, A., Raj, V., Saini, V., Khan, G., Singh, H., Mishra, A., & Paliwal, S. (2024) · Current Alzheimer Research · doi:10.2174/0115672050361294241211071813 · Cited by 3
Wang, F., Jing, Z., Wang, Q., Li, M., Lu, B., Huo, A., Zhao, C., Zhou, H., Liang, W., Hu, W., et al. (2025) · Brain and Behavior · doi:10.1002/brb3.70283 · Cited by 4
Tu, Q., Zhou, R., Lv, G., Wan, Z., Chen, S., & Que, B. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1503727 · Cited by 3
Shah, F. A., Qadir, H., Khan, J., & Faheem, M. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.03.064 · Cited by 4
Comprehending Alzheimer's Disease: Molecular Mechanisms and Treatment Strategies
Rathee, S., Pandey, V., Soni, S., Sen, D., & Jain, S. (2025) · Current Alzheimer Research · doi:10.2174/0115672050368798250626075628 · Cited by 8
Bridging prion biology and Alzheimer’s disease: from pathogenic seeds to precision therapeutics
Wang, W., Feng, Z., Shu, L., Hu, Y., Chen, Y., Zhang, B., & Huang, H. (2025) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2025.1660151 · Cited by 3
“…covers the failure of the BACE inhibitor Verubecestat in phase III trials (2014) (Egan et al., 2018), the proposal of A β ’s “prion-like” propagation (2014) (Jucker and Walker, 2018; Shi et al., 2021), and Solanezumab’s lack of cognitive benefit despite A β clearance (2016) (Honig et al., 2018).”
Camins, A., Ettcheto, M., & Busquets, O. (2019) · Neural Regeneration Research · doi:10.4103/1673-5374.257513 · Cited by 3
“However, clinical trials with compounds like solanezumab, a humanized monoclonal antibody that recognizes soluble Aβ and increases its clearance from the brain, has failed to slow the clinical progression of mild-to-moderate AD patients (Honig et al., 2018).”
BackgroundPreventing Cognitive Decline and Dementia
Shea, Y. F., & DeKosky, S. T. (2019) · Cambridge University Press eBooks · doi:10.1017/9781108554350.019 · Cited by 4
Update on Treatments for Cognitive Decline in Alzheimer’s Disease
Kriebel-Gasparro, A. M. (2020) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2019.12.016 · Cited by 4
Dicer1 promotes Aβ clearance via blocking B2 RNA-mediated repression of apolipoprotein E
Wang, Y., Lian, M., Xiu, X., Zhang, Z., Song, L., & Wu, S. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.166038 · Cited by 4
Barnes, J. N., Burns, J. M., Bamman, M. M., Billinger, S. A., Bodine, S. C., Booth, F. W., Brassard, P., Clemons, T. A., Fadel, P. J., Geiger, P. C., et al. (2022) · Brain Plasticity · doi:10.3233/bpl-220146 · Cited by 4
“To date there 49 are no effective treatment options for AD patients, 50 and pharmaceutical trials have generally resulted in 51 failure [5].”
BackgroundKamran, S., Tamene, Y., Mody, S. P., Sadiq, K. O., Shivakumar, Y. M., Burra, E. K., & Ramphall, S. (2023) · Cureus · doi:10.7759/cureus.43984 · Cited by 5
“EXPEDITION 3 [25] was conducted for further investigations into the efficacy of Solanezumab.”
BackgroundInfluentialOno, M., Ito, T., Yamaki, S., Hori, Y., Zhou, Q., Zhao, X., Muramoto, S., Yamamoto, R., Furuyama, T., Sakata‐Haga, H., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e28821 · Cited by 3
Khalili-Moghadam, F., Nejad, J. H., Badri, T., Sadeghi, M., & Gharechahi, J. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e37556 · Cited by 3
“Efforts have been made to develop therapeutics targeting soluble and insoluble A β or the enzymes responsible for amyloid precursor protein (APP) cleavage as potential AD treatments, albeit with disappointing outcomes [21].”
BackgroundSang, Z. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23932-8.00035-2 · Cited by 3
Alzheimer’s Disease: Epidemiology, Etiology, Risk Factors, and Future Predictions
Jojo, G. M., Johnson, J., Kuppusamy, G., & Karri, V. V. S. R. (2024) · Springer eBooks · doi:10.1007/978-981-96-0259-9_3 · Cited by 4
Kim, Y. J., Lim, H.-S., Kim, J., Na, M., & Jeong, S. (2020) · Natural Product Communications · doi:10.1177/1934578x20924859 · Cited by 4
Thiamine pyrophosphokinase deficiency induces Alzheimer’s pathologyPreprint
Sang, S., Qian, T., Cai, F., Qiu, H., Xu, Y., Zhang, Y., Zhang, Q., Huang, S., Jiang, D., Wu, Y., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.09.141358 · Cited by 4
Wang, D., Ma, X., Schulz, P. E., Jiang, X., & Kim, Y. (2023) · medRxiv · doi:10.1101/2023.10.13.23296985 · Cited by 4
Jeremic, D., Navarro‐López, J. D., & Jiménez‐Díaz, L. (2024) · medRxiv · doi:10.1101/2024.03.31.24305134 · Cited by 4
Cognitive Enhancers and Treatments for Alzheimer’s Disease
Devanand, D. P., & Fremont, R. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_139-1 · Cited by 4
Gitlin-Leigh, G., Wilson, J., Howard, R., Howard, R. J., & Costello, H. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251378156 · Cited by 3
Shan, G., & Cummings, J. L. (2025) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70186 · Cited by 4
“12,13 These failuresare attributable tochanceoutcomes(especiallyunequal sizes or imbalanced features of the subgroups assigned to drug or placebo), unadjusted multiple comparisons, failure to prespecify the subgroup and the direction of anticipated differences, the impact of confounding factors on…”
Aβ antibodies target not only amyloid plaques but also distinct brain cells and vessels
Wen, G., Lindblom, N., Zhan, X., Garcia, M. G., Deierborg, T., Kobro‐Flatmoen, A., & Gouras, G. K. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71121 · Cited by 3
Mohs, R. C., Beauregard, D. W., Hughes, L., Cordell, C. B., Levey, A. I., Rathore, S., Seyfried, N. T., Johnson, E. C. B., Nicodemus‐Johnson, J., Christensen, J. R., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71085 · Cited by 2
The aggregation of amyloid-β: from condensation, nucleation, and conformation to targeting therapy
Chen, B., Chen, T., Sun, Z., Liu, L., Jia, Y., Ji, Y., Wang, J., Sun, F., & Huang, Y. (2026) · Life Sciences · doi:10.1016/j.lfs.2026.124397 · Cited by 3
Fox, N. C., Kohlhaas, S. L., & Schott, J. M. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00789-0 · Cited by 3
Zantek, N. D., Alquist, C. R., Hofmann, J. C., Klingel, R., Levenbrown, Y., Onwuemene, O. A., Patidar, G. K., Patriquin, C. J., Raval, J. S., Sanchez, A. P., et al. (2026) · Journal of Clinical Apheresis · doi:10.1002/jca.70141 · Cited by 4
Reed, C. C., Happich, M., Raskin, J., Tockhorn‐Heidenreich, A., & Belger, M. A. (2019) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2019.4 · Cited by 2
Recent Advances in Alzheimer’s Disease Treatments with Therapeutic Antibodies to Amyloid-β
Yang, J., & Bradford, A. (2022) · Journal of Student Research · doi:10.47611/jsrhs.v11i3.3453 · Cited by 2
Byun, K. (2023) · Exercise Science · doi:10.15857/ksep.2023.32.1.11 · Cited by 3
Lin, Q., Bian, W., Wang, D., Ming, Z., Zhang, Y., Zhang, L., & Fu, L. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221088 · Cited by 2
Advancing Alzheimer’s care: a novel therapy with lecanemab
Teli, A., & Dhande, P. P. (2023) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-023-00747-y · Cited by 3
“Several secondary clinical endpoints, including cognitive and functional measures, did favor solanezumab, but the benefit was almost non-comparable [27].”
BackgroundNeuroglia targeting nano-therapeutic approaches to rescue aging and neurodegenerating brain
Sharma, M., Aggarwal, N., Mishra, J., & Panda, J. J. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.123950 · Cited by 3
Nonarteritic Anterior Ischemic Optic Neuropathy and the Risk of Dementia: A Nationwide Cohort Study
Kim, J., Han, K., Jung, J., Park, K., & Oh, S. Y. (2024) · Neurology · doi:10.1212/wnl.0000000000209657 · Cited by 2
“Current and emerging drug therapies in Alzheimer’s disease: A pathophysiological Perspective”
Aparajita, A., Jain, U., & Srivastava, P. (2024) · Neuroscience · doi:10.1016/j.neuroscience.2024.11.078 · Cited by 2
Ultra-fast [18F]florbetapir PET imaging using the uMI Panorama PET/CT system
Yang, X., Wu, M., Liang, M., Zhang, H., Li, B., Mao, C., Dong, L., Wang, Y., Xing, H., Ren, C., et al. (2024) · EJNMMI Physics · doi:10.1186/s40658-024-00712-5 · Cited by 3
Symptomatic vs. Disease-Modifying Therapies
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202.011 · Cited by 2
Pharmacotherapy for Alzheimer’s disease: what’s new on the horizon?
Khoury, R., Gallop, A., Roberts, K., Grysman, N., Lu, J., & Grossberg, G. T. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2097868 · Cited by 2
Regulation of Caenorhabditis Elegans model in Alzheimer’s Disease
Jing, Y. (2020) · E3S Web of Conferences · doi:10.1051/e3sconf/202018503043 · Cited by 2
“However, solanezumab does not show much efficiency when it comes to moderate or severe AD patients [38].”
BackgroundAmyloid peptide exerts a rapid induction of Dicer1 protein in neuron via reducing phosphorylation
Wang, Y., Xiu, X., & Wu, S. (2021) · Neurochemistry International · doi:10.1016/j.neuint.2021.105210 · Cited by 2
Cognitive Enhancers and Treatments for Alzheimer’s Disease
Devanand, D. P., & Fremont, R. (2024) · Springer eBooks · doi:10.1007/978-3-030-51366-5_139 · Cited by 4
Sequential parallel comparison design with two coprimary endpoints
Homma, G., & Daimon, T. (2019) · Pharmaceutical Statistics · doi:10.1002/pst.1987 · Cited by 2
“The sample size calculation for the CD is performed by setting in the formula (5), w1 = w2 = 1, which is equivalent to only stage 1 of the SPCD, and a = .”
BackgroundMethodInfluentialPharmakologische Therapie der Alzheimer-Demenz: Aktueller Stand und Perspektiven
Müller, P., Fendt, M., & Müller, N. (2019) · Der Internist · Cited by 2
Idalopirdine: another disappointment for people with dementia
Couteur, D. G. L., Bateman, B., & Brayne, C. (2018) · BMJ · doi:10.1136/bmj.k753 · Cited by 2
Pharmacotherapy for Alzheimer’s disease: a perspective on treatment strategies in Japan
Nagata, T., Nakajima, S., Shinagawa, S., Noda, Y., & Mimura, M. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1502271 · Cited by 2
Tau Based Therapeutics: Alternative Approaches in the War on Alzheimer's Disease
Grundman, M. J. (2019) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2019.13 · Cited by 2
Thermodynamic and kinetic design principles for protein aggregation inhibitorsPreprint
Michaels, T. C. T., Šarić, A., Meisl, G., Heller, G. T., Curk, S., Arosio, P., Linse, S. S., Dobson, C. M., Vendruscolo, M., & Knowles, T. P. J. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.02.22.960716 · Cited by 2
Pronko, P. S., Zimatkin, S. M., & Kuz'mich, A. B. (1994) · PubMed · Cited by 2
Wei, H., Masurkar, A. V., & Razavian, N. (2021) · medRxiv · doi:10.1101/2021.05.05.21256720 · Cited by 3
Stefanovski, L., Meier, J. M., Pai, R. K., Triebkorn, P., Lett, T. A. P., Martin, L., Bülau, K., Hofmann‐Apitius, M., Solodkin, A., McIntosh, A. R., et al. (2020) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/4t5qa · Cited by 2
(2021) · Wiley eBooks · doi:10.1002/9781119870203.mpg006 · Cited by 2
Qiu, Y.-H., Liu, M., Zhan, J., Liu, L., Zheng, J., Wu, D., Wu, G., Cai, Y., & Zhang, S. (2023) · medRxiv · doi:10.1101/2023.11.20.23298794 · Cited by 3
Kremer, P. H. C., & Groeneveld, G. J. (2022) · Medical Research Archives · doi:10.18103/mra.v10i9.3042 · Cited by 1
Alzheimer’s Disease: Cellular and Pharmacological Aspects
Aranda-Abreu, G. E., Rojas-Durán, F., Hernández‐Aguilar, M. E., Herrera‐Covarrubias, D., Chi-Castañeda, D., Toledo‐Cárdenas, M. R., & Suárez-Medellín, J. M. (2024) · Geriatrics · doi:10.3390/geriatrics9040086 · Cited by 2
“It was applied at a dose of 1600 mg intravenously every 4 weeks for 240 weeks [30,31].”
Monoclonal antibody therapy in Alzheimer’s disease: an overview and vision
Bentley, J. H., Bishop, L. E., & Broussard, J. I. (2024) · Brain Network and Modulation · doi:10.4103/bnm.bnm_14_23 · Cited by 2
Immunotherapy of Alzheimer’s Disease
Tondo, G., Marchi, F. D., Anselmi, M., & Comi, C. (2024) · Springer eBooks · doi:10.1007/978-3-031-68237-7_51 · Cited by 1
Sample size determination for a study with variable follow-up time
Shan, G., Zhang, Y., Lu, X., Li, Y., Lu, M., & Li, Z. (2025) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2025.2469879 · Cited by 1
“In the AD trial to test the effectiveness of solanezumab at the dose level of 400 mg (Honig et al. 2018), patients in the treatment group received solanezumab every 4 weeks for 76 weeks, followed by 4 weeks of assessments.”
Prospects for treating Alzheimer’s disease
Васильевна, В. Н., Novikov, D. K., Vekhova, K. A., Zhuk, A. M., Klimanovich, D. L., Isaikin, A. I., & Zakharov, V. V. (2025) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro202512504254 · Cited by 1
Qi, W., Long, Y., Li, Z., Zhao, Z., Shi, J., Xie, W., Wang, L., Tan, Y., Zhou, T., Liang, M., et al. (2024) · eLife · doi:10.7554/elife.99462.3 · Cited by 6
Optic neuritis as a link between autoimmunity and dementia risk
Kim, J., Han, K., Jung, J., Oh, S. Y., Park, K., & Min, J. (2025) · Communications Medicine · doi:10.1038/s43856-025-01050-y · Cited by 1
Wang, X., Huang, S.-S., Wang, M., Lin, J., Wang, J., Ren, J., He, C.-F., Xue, W.-J., Wang, Y., Wang, X., et al. (2025) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2025.1617543 · Cited by 1
Advancement in the animal model-based therapeutics in neurodegenerative diseases
Pal, D., Das, P., Ghosh, P., Gupta, S., Basak, P., & Nandi, S. K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33877-9.00007-0 · Cited by 1
Katiyar, D., & Manish, M. (2025) · Letters in Drug Design & Discovery · doi:10.1016/j.lddd.2025.100126 · Cited by 2
Kniazev, R. (2025) · Cureus · doi:10.7759/cureus.96090 · Cited by 1
“Lessons from Alzheimer’s disease (AD) support intervening earlier in the pathogenic process: the antiamyloid antibody lecanemab slowed cognitive decline when given in early AD [2], whereas similar treatments failed to show benefit in late-stage disease [18].”
Evolving Pharmacotherapies Involving Neuroimmune Crosstalk
Maurya, R., Ali, K., Soni, H., Mhatre, A., & Naqvi, S. (2026) · Springer eBooks · doi:10.1007/978-981-95-5088-3_12 · Cited by 1
Rogacz, Z., Pacuła, W., Strzałka‐Mrozik, B., & Turek, A. (2026) · Applied Sciences · doi:10.3390/app16052554 · Cited by 2
A review of plant-derived products regulating amyloid beta-degrading enzymes in Alzheimer’s disease
Honaramouz, B., Imenshahidi, M., & Hosseinzadeh, H. (2026) · Phytomedicine · doi:10.1016/j.phymed.2026.158053 · Cited by 1
Monoclonal antibodies and small molecules: on the cutting edge of Alzheimer’s disease therapy
Ouro, A., Ben-Dor, G. A., Debasa‐Mouce, M., Gulkarov, S., Leon, J. D., Castro‐Mosquera, M., Sobrino, T., Bougea, A. M., & Reiss, A. B. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1766762 · Cited by 1
“…EXPEDITION2NCT00904683 trials ( > 2,000 mild-to-moderate AD patients) and the subsequent prodromal AD EXPEDITION3 trialNCT01900665,solanezumab failed to meet cognitive endpoints despite target engagement, leading to program termination in 2016 (Lozupone et al., 2024; Honig et al., 2018).”
Stepanchuk, A. A., Joseph, J. T., Lashley, T., & Stys, P. K. (2026) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2026.04.009 · Cited by 1
Advances in the treatment of Alzheimer’s disease
Goceroglu, R. T., & Hacımüftüoğlu, A. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1819165 · Cited by 2
“It was found that solanezumab did not provide a significant benefit in terms of cognitive decline in patients with mild Alzheimer’s disease; furthermore, these findings failed to replicate the secondary outcomes observed in previous studies (Honig et al., 2018).”
Corriveau‐Lecavalier, N., Falgàs, N., Putcha, D., Graff‐Radford, J., Yong, K. X. X., Boon, B. D. C., Mohanty, R., Westman, E., Groot, C., Jones, D. T., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71521 · Cited by 1
Predicting cognitive function in Alzheimer's clinical trials via amyloid β‐protein biomarkers
Sui, Z., Feng, A., Gong, Y., Zha, S., Lv, Y., Zheng, Q., Li, L., & Wang, Y. (2026) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70665 · Cited by 1
Sharma, A., Suresh, V., Kola, P. R., Raj, R. A., Javairia, F., Nithyanandam, A., Kaur, A., Arora, H., Uwishema, O., Gorty, D., et al. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261466097 · Cited by 3
Is amyloid beta peptide a driver of inflammaging?
Kechko, O. I., Moskalev, A. A., Franceschi, C., Mitkevich, V. A., & Makarov, A. А. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103280 · Cited by 1
Pharmacists a valuable resource for patients with Alzheimer disease and their caregivers
Ryan, M. A. (2019) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2019.09.019 · Cited by 1
Disease Subtypes: The Promise and the Fallacy
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202.006 · Cited by 1
Potential Applications of Artificial Intelligence in Clinical Trials for Alzheimer’s Disease
Seo, Y., Jang, H., & Lee, H. (2022) · Life · doi:10.3390/life12020275 · Cited by 25
Cummings, J. L. (2022) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2022.25 · Cited by 1
“A Phase 3 trial in mild AD dementia did not meet its primary outcome; it is uncertain if limited efficacy was shown (19).”
The Diagnostic Potential of Circulating Autoantibodies to Amyloid-β in Alzheimer’s Disease
Xu, G.-Y., Liu, Y., Zeng, X., Chen, D., Zeng, G., Fan, D., Liu, Y.-H., & Wang, Y. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230252 · Cited by 1
Emerging Treatments for Alzheimer's Disease
Zhao, Z. (2023) · Highlights in Science Engineering and Technology · doi:10.54097/hset.v54i.9778 · Cited by 2
“For instance, aducanumab and solanezumab are two examples of amyloid-beta-targeting monoclonal antibodies that have shown promise in reducing amyloid plaque buildup and halting cognitive decline in early-stage Alzheimer's disease [4,5].”
Chen, H., Wang, X., Zhang, J., & Xie, D. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1375234 · Cited by 3
“…simple sentences; and the ability to complete the relevant scale assessments; and ⑤ had a Mini Mental State Examination (MMSE; Zhang et al., 1999; Honig et al., 2018; Arevalo-Rodriguez et al., 2021) score ≤ 26 分 (a score of 20–26 indicated mild cognitive impairment) and a Montreal Cognitive…”
BackgroundThe potential use of natural killer cells to treat Alzheimer's disease: Can nutrition play a role?
Dong, A., Huang, Y., Chen, H., Liu, R., Wu, W., Gao, H., Wang, C., Yu, J., & Wang, L. (2024) · eFood · doi:10.1002/efd2.145 · Cited by 1
Wihadmadyatami, H., & Kusindarta, D. L. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15717-2.00120-7 · Cited by 1
Therapeutic Strategies in Neurodegenerative Diseases
Eid, A. M., Faridar, A., & Appel, S. H. (2024) · Springer eBooks · doi:10.1007/978-3-031-68237-7_39 · Cited by 2
Feng, G., Zheng, C., & Hui, J. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.07.049 · Cited by 2
Geriatrics update 2018: Challenges in mental health, mobility, and postdischarge care
Kim, L. D., & Hashmi, A. Z. (2018) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.85a.18059 · Cited by 1
Takeuchi, J., Kikukawa, T., Saito, H., Hasegawa, I., Takeda, A., Hatsuta, H., Kawabe, J., Wada, Y., Mawatari, A., Igesaka, A., et al. (2019) · The Open Biomedical Engineering Journal · doi:10.2174/1874120701913010055 · Cited by 1
Lee, M. J. (2019) · UKnowledge (University of Kentucky) · doi:10.13023/etd.2019.169 · Cited by 1
Nakamura, T., Matsumura, T., Yamamoto, Y., & Senda, M. (2019) · PubMed · doi:10.18893/kakuigaku.oa.1802 · Cited by 1
The EU/US Task Force's Future for Anti-Amyloid Trials: Faites Vos Jeux
Schneider, L. S. (2020) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2020.29 · Cited by 1
“One example, the third, phase 3 solanezumab trial (4) resulted in a P value = .”
Erstes kausal wirkendes Medikament gegen Alzheimer? Die FDA lässt Aducanumab zu
Häger, K. (2021) · Der Nervenarzt · doi:10.1007/s00115-021-01182-1 · Cited by 1
Beneficial Effects of Anthocyanins on Nervous System
Li, B., Wang, L., Bai, W., Chen, W., Chen, F., & Shu, C. (2021) · Springer eBooks · doi:10.1007/978-981-16-7055-8_17 · Cited by 1
New Perspectives for Treatment in Alzheimer’s Disease
Loureiro, J. C., Silva, L. F. D. A. L. E., Pais, M. V., & Forlenza, O. V. (2022) · Springer eBooks · doi:10.1007/978-3-030-94383-7_10 · Cited by 1
Alzheimer’s Disease: What Do We Know About It and How Can We Tackle It?
Mirpuri, B. (2022) · International journal of high school research · doi:10.36838/v4i2.13
Metadata
- Authors
- Honig, L. S., Vellas, B., Woodward, M., Boada, M., Bullock, R., Borrie, M., Hager, K., Andreasen, N., Scarpini, E., Liu-Seifert, H., Case, M., Dean, R. A., Hake, A., Sundell, K., Poole Hoffmann, V., Carlson, C., Khanna, R., Mintun, M., DeMattos, R., Selzler, K. J., & Siemers, E.
- Affiliations
- Université Toulouse III - Paul Sabatier (FR)
- From the Department of Neurology and Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, Columbia University Medical Center, New York (L.S.H.); Gérontopôle, Centre Hospitalier Universitaire Toulouse, Unité Mixte de Recherche INSERM Unité 1027 Université Toulouse III–Paul Sabatier, Toulouse, France (B.V.); Austin Health Continuing Care Clinical Service Unit, Heidelberg, and the University of Melbourne, Melbourne, VIC — both in Australia (M.W.); Fundació ACE, Alzheimer Research...
- Western University (CA)
- Karolinska University Hospital (SE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-01-25
- Volume
- 378
- Issue
- 4
- Pages
- 321-330
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2787612390
- Cited by
- 1,049
- References
- 27
- Citations by year
- 2026: 48 · 2025: 93 · 2024: 121 · 2023: 123 · 2022: 136 · 2021: 129 · 2020: 169 · 2019: 136 · 2018: 91
- FWCI
- 90.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- IUScholarWorks (Indiana University) (submittedVersion)
- Publisher
- Funders
- Eli Lilly and Company
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- solanezumab, Alzheimer's disease, mild dementia, amyloid-beta, humanized monoclonal antibody, amyloid-beta clearance, cognitive decline, florbetapir PET, cerebral edema, treatment efficacy, amyloid plaques, neurofibrillary tangles
- MeSH terms
- Mental Status and Dementia Tests, Activities of Daily Living, Aged, Aged, 80 and over, Alzheimer Disease, Double-Blind Method, Female, Humans, Immunotherapy, Infusions, Intravenous, Male, Middle Aged, Peptide Fragments, Biomarkers, Amyloid beta-Peptides, Treatment Failure, Positron-Emission Tomography, Plaque, Amyloid, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.